Search results
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
Morningstar· 5 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion ...
A Guide for Living With COPD
Prevention via Yahoo News· 7 days agoThis chronic respiratory disease most commonly affects women aged 65 and older. But there are ways to manage the symptoms and slow down its progression.
A Lump in My Groin Led to a Stage 4 Melanoma Diagnosis When I Was Just 22
Self via Yahoo News· 7 days agoOtherwise, it wasn’t as bad as I thought it would be. After a scary bout of liver problems that...
Multiple sclerosis is on the rise in Australia, but it's not all bad news
Medical Xpress· 6 days agoWhile the number of people with the disease has gone up significantly in the past decade, largely...
What is hypogonadism?
Medical News Today· 6 days agoHypogonadism is a medical term that describes when the body does not produce sufficient sex hormones. “Hypo” means low or below normal levels, while...
Does Dandruff Cause Hair Loss? Dermatologists Weigh In + Share 4 Tricks To Stop Flaking
The Sacramento Bee· 6 days agoTo find out, we asked experts to explain what dandruff actually is, how ketoconazole shampoo may help, plus more ways to find relief. Dandruff is a symptom of seborrheic dermatitis, says Heather ...
Angela Rose: Treat your pain in the neck with Myofascial Release
The Grass Valley Union· 4 days agoA woman came in with a stiff neck and she could barely turn her head, she was having trouble looking...
A Guide for Living With COPD
Prevention· 7 days agoIn the past, chronic obstructive pulmonary disease (COPD)—a lung condition that limits airflow into your lungs and causes difficulty breathing—was...
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with...
telegraphherald.com· 5 days agoThe positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely
